[THE INFLUENCE OF DEFICIT OF ENDOGENOUS NEUROPEPTIDES ON THE CLINICAL COURSE OF CORONARY HEART DISEASE]

Klinicheskaia Meditsina
|October 11, 2018
PubMed

Insights

Lower blood beta-endorphin levels in coronary heart disease (CHD) patients with metabolic syndrome (MS) correlate with cardiovascular risks. Dalargin therapy improved these markers, increasing beta-endorphin and HDL cholesterol while reducing inflammation and metabolic dysfunction.

Area of Science:

  • Cardiology
  • Endocrinology
  • Immunology

Background:

  • Coronary heart disease (CHD) patients with metabolic syndrome (MS) exhibit altered blood beta-endorphin levels.
  • These alterations are potentially linked to cardiovascular risk factors, including inflammation and metabolic dysregulation.

Purpose of the Study:

  • To investigate the relationship between blood beta-endorphin levels and cardiovascular risk factors in CHD patients with MS.
  • To evaluate the efficacy of dalargin therapy in correcting these imbalances.

Main Methods:

  • A randomized study involving 123 CHD patients with MS, comparing standard therapy to standard therapy plus dalargin.
  • Biochemical and immunological markers were assessed before and after a 3-month treatment period.

Main Results:

  • A significant inverse correlation was observed between beta-endorphin and leptin, insulin, cortisol, TNF-a, IL-6, oxidized LDL, and triglycerides.
  • Dalargin therapy significantly increased beta-endorphin and HDL cholesterol levels.
  • Dalargin therapy markedly reduced leptin, insulin, cortisol, TNF-a, IL-6, LDL, and triglyceride levels compared to standard therapy.

Conclusions:

  • Decreased beta-endorphin in CHD with MS is associated with increased atherogenicity, hyperinsulinemia, hypercortisolemia, and inflammation.
  • Dalargin supplementation enhances beta-endorphin levels, exerts anti-atherogenic effects, and reduces inflammatory and metabolic risk factors.

Related Concept Videos

Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
373
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
587
Factors Influencing Heart Rate01:30

Factors Influencing Heart Rate

The heart rate, or pulse rate, is a vital indicator of cardiovascular health. It reflects the number of times the heart beats per minute. Various physiological and environmental factors influence heart rate, increasing or decreasing cardiac output. Understanding these factors is crucial for assessing heart function and identifying potential health issues.
Let us explore the significant factors affecting heart rate, including age, body temperature, posture, acute pain, chemical influences,...
6.4K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.1K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
451
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
430